Get the Stockscreener App
19.93
0.20%
0.04
Overview
News
Price History
Option Chain
Financials
Why TEVA Down?
Discussions
Forecast
Stock Split
Dividend History
Teva Pharmaceutical Industries Ltd Adr stock is traded at $19.93, with a volume of 9.14M.
It is up +0.20% in the last 24 hours and up +20.06% over the past month.
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
See More
Previous Close:
$19.89
Open:
$19.78
24h Volume:
9.14M
Relative Volume:
0.83
Market Cap:
$22.86B
Revenue:
$16.70B
Net Income/Loss:
$-157.13M
P/E Ratio:
-128.58
EPS:
-0.155
Net Cash Flow:
$1.19B
1W Performance:
+5.17%
1M Performance:
+20.06%
6M Performance:
+20.93%
1Y Performance:
+10.66%
1-Day Range:
$19.60
$19.98
1-Week Range:
$18.77
$19.98
52-Week Range:
$12.46
$22.80
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Name
Teva Pharmaceutical Industries Ltd Adr
Sector
Phone
972 (3) 914-8213
Address
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.93 | 22.45B | 16.70B | -157.13M | 1.19B | -0.155 |
|
ZTS
Zoetis Inc
|
148.20 | 66.22B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.10 | 48.29B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.99B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
UTHR
United Therapeutics Corp
|
405.02 | 17.93B | 2.99B | 1.21B | 1.13B | 25.06 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Goldman | Buy |
| May-28-25 | Initiated | Truist | Buy |
| May-12-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-10-24 | Upgrade | Argus | Hold → Buy |
| Mar-08-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-12-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-23-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Upgrade | Piper Sandler | Underweight → Neutral |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Nov-27-23 | Upgrade | UBS | Neutral → Buy |
| Jul-06-23 | Upgrade | UBS | Sell → Neutral |
| May-25-23 | Initiated | Morgan Stanley | Equal-Weight |
| May-18-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-19-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-14-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | UBS | Neutral → Sell |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Aug-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-14-22 | Resumed | UBS | Neutral |
| May-17-22 | Upgrade | BofA Securities | Underperform → Neutral |
| May-04-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Apr-05-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-25-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-27-22 | Downgrade | Argus | Buy → Hold |
| Oct-28-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-04-21 | Downgrade | UBS | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-25-20 | Initiated | Oppenheimer | Perform |
| Aug-06-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-27-20 | Resumed | Goldman | Neutral |
| Jun-01-20 | Upgrade | SunTrust | Hold → Buy |
| Apr-24-20 | Resumed | Citigroup | Neutral |
| Apr-06-20 | Upgrade | UBS | Neutral → Buy |
| Feb-24-20 | Downgrade | Edward Jones | Hold → Sell |
| Nov-12-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-07-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-19-19 | Initiated | Wolfe Research | Peer Perform |
| Jul-15-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Jul-05-19 | Upgrade | Argus | Hold → Buy |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Jun-03-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-30-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| May-28-19 | Downgrade | UBS | Buy → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Mar-07-19 | Resumed | UBS | Buy |
View All
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News
Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy - Ariva
Teva stock rises on launch of first generic weight loss GLP-1 drug - Investing.com Nigeria
Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN
Teva stock rises on launch of first generic weight loss GLP-1 drug By Investing.com - Investing.com South Africa
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss - Placera.se
TEVA Stock Price and Chart — TASE:TEVA - TradingView
Earnings call transcript: Teva’s Q2 2025 earnings beat fails to lift revenue - Investing.com
Nootropics Market Size Projected to Attain USD 19.53 Billion by 2034 - GlobeNewswire Inc.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Navigating a Year of Volatility - investchronicle.com
Teva's AJOVY Receives FDA Approval for Pediatric Migraine Treatment - AInvest
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Ariva
TEVA’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com
Teva's Pivot to Growth Strategy Underway as Innovative Portfolio Impresses and Pipeline Looks Solid - Morningstar
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components - Ariva
Head-To-Head Contrast: Teva Pharmaceutical Industries (NYSE:TEVA) & Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Drops -2.31%, Turning Investors Away - Stocksregister
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?26.06.25News - Ariva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by Yousif Capital Management LLC - Defense World
Can Teva- Pharmaceutical Industries Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Stocks Generating Improved Relative Strength: Teva Pharmaceutical ADR - MSN
Teva: New Long-Term Targets and Sold Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
Teva: New Long-Term Targets and Solid Pipeline Reaffirm Our Favorable Outlook; Shares Undervalued - Morningstar
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Yahoo Finance
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.
Teva Earnings: Innovation Propels Sales and Generics Show Stability in Solid Start to the Year - Morningstar
Teva and Alvotech stocks jump on FDA approval of SELARSDI - Investing.com
Teva and Alvotech stocks jump on FDA approval of SELARSDI By Investing.com - Investing.com Canada
There Are Mixed Signals on the Chart for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) - uspostnews.com
Digi Power X Inc (DGXX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Market Analysts see Norwegian Cruise Line Holdings Ltd [NCLH] gaining to $21. Time to buy? - dbtnews.com
PG&E Corp [PCG] Revenue clocked in at $24.54 billion, down -14.37% YTD: What’s Next? - dbtnews.com
Greenwave Technology Solutions Inc [GWAV] Is Currently 12.13 above its 200 Period Moving Avg: What Does This Mean? – The DBT News - dbtnews.com
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Performance and Fundamentals Dashboard tells a completely different story – Sete News - Sete News
Raymond James slashes price target on Adma Biologics Inc [ADMA] – find out why. - dbtnews.com
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: A Year of Highs and Lows - investchronicle.com
Company’s Banking Stock: Dissecting a 37.52% Quarterly Revenue Decline Amid Growth - investchronicle.com
NEOV’s Market Whiplash: -48.46% YTD Decline, 15.24% Rise in 30 Days - investchronicle.com
Adagio Medical Holdings Inc (ADGM) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):